HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to CHRONOS-3 TRIAL: COMBINATION OF COPANLISIB-RITUXIMAB The conclusion is based on data from the phase III trial CHRONOS-3, s study sponsored by Bayer AG.The results were presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15, 2021, and concurrently published in The Lancet Oncology. “We are glad to see that copanlisib could be safely combined with rituximab for the long-term treatment of patients with HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEX DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTED The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial IMMUNOTHERAPY MARKET ESTIMATED TO REACH U.S. $115 BILLION Immunotherapy Market Estimated to Reach U.S. $115 Billion by 2023. According to a new report published by ReportsnReports, the Immunotherapy is expected to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. HIGHLIGHTS OF PRESCRIBING INFORMATION HEPATOTOXICITY FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an

FDA approved test.

ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

HIGHLIGHTS OF PRESCRIBING INFORMATION ADJUVANT … Subsequent doses at 6mg/kg as an intravenous infusion over 30–90 minutes every three weeks . Extending adjuvant treatment beyond one year is not recommended . HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to CHRONOS-3 TRIAL: COMBINATION OF COPANLISIB-RITUXIMAB The conclusion is based on data from the phase III trial CHRONOS-3, s study sponsored by Bayer AG.The results were presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15, 2021, and concurrently published in The Lancet Oncology. “We are glad to see that copanlisib could be safely combined with rituximab for the long-term treatment of patients with HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEX DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTED The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial IMMUNOTHERAPY MARKET ESTIMATED TO REACH U.S. $115 BILLION Immunotherapy Market Estimated to Reach U.S. $115 Billion by 2023. According to a new report published by ReportsnReports, the Immunotherapy is expected to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. HIGHLIGHTS OF PRESCRIBING INFORMATION HEPATOTOXICITY FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an

FDA approved test.

ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

HIGHLIGHTS OF PRESCRIBING INFORMATION ADJUVANT … Subsequent doses at 6mg/kg as an intravenous infusion over 30–90 minutes every three weeks . Extending adjuvant treatment beyond one year is not recommended . STUDIES CONFIRM SAFETY AND EFFECTIVENESS OF COVID-19 Vaccination among cancer patients, hardest hit by the pandemic work very well. It's important to stress how well these patients did with

vaccines

WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to COMBINATION THERAPY ACHIEVED DURABLE REMISSION FOR A new study demonstrated that ibrutinib and venetoclax were effective when given together for high-risk and older patients with the disease. IMMUNOTHERAPY AFTER SURGERY EXTENDS DISEASE-FREE SURVIVAL Immunotherapy after surgery significantly improved disease-free survival for patients with clear-cell renal carcinoma a common type of

kidney cancer

GLIOBLASTOMA TRIAL WITH PERSONALIZED CANCER VACCINE SHOWS Data from the multi-center Phase 2 clinical trial of AV-GBM-1 (AIVITA Biomedical; NCT03400917), a personalized cancer vaccine, in patients 18 years or older with newly diagnosed glioblastoma (GBM) demonstrated a considerable increase in progression-free survival (PFS). RESEARCHERS FIND POSSIBLE LINK BETWEEN PROSTATE CANCER AND There may be an association between a few polymorphic variants of genes controlling neurotransmitter metabolism and the prognosis of

prostate cancer.

NIVOLUMAB + IPILIMUMAB SHOWS CONTINUED SURVIVAL IN Updated results from CheckMate-214 study (NCT02231749) show that more than 50% of patients treated with a combination of nivolumab (Opdivo®; Bristol Meyers Squibb), a programmed death-1 (PD-1) immune checkpoint inhibitor designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response, and ipilimumab (Yervoy®; Bristol Meyers Squibb)* were ADVANCING TREATMENT OPTIONS WITH IMMUNOTHERAPIES IN NON Antibody-drug conjugates Polatuzumab vedotin is a first-in-class anti-CD79b ADC. The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. SINGLE AND DUAL IMMUNOTHERAPY REGIMENS MAY OFFER IMPROVED Dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those positive for the immune checkpoint protein PD-L1. CLINICAL DEVELOPMENT The latest news and updates about clinical development in oncology and hematology from Onco'Zine and ADC Review | J. Antibody-drug

Conjugates.

HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to CHRONOS-3 TRIAL: COMBINATION OF COPANLISIB-RITUXIMAB The conclusion is based on data from the phase III trial CHRONOS-3, s study sponsored by Bayer AG.The results were presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15, 2021, and concurrently published in The Lancet Oncology. “We are glad to see that copanlisib could be safely combined with rituximab for the long-term treatment of patients with HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEX DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTED The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial IMMUNOTHERAPY MARKET ESTIMATED TO REACH U.S. $115 BILLION Immunotherapy Market Estimated to Reach U.S. $115 Billion by 2023. According to a new report published by ReportsnReports, the Immunotherapy is expected to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. HIGHLIGHTS OF PRESCRIBING INFORMATION HEPATOTOXICITY FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an

FDA approved test.

ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

HIGHLIGHTS OF PRESCRIBING INFORMATION ADJUVANT … Subsequent doses at 6mg/kg as an intravenous infusion over 30–90 minutes every three weeks . Extending adjuvant treatment beyond one year is not recommended . HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to CHRONOS-3 TRIAL: COMBINATION OF COPANLISIB-RITUXIMAB The conclusion is based on data from the phase III trial CHRONOS-3, s study sponsored by Bayer AG.The results were presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15, 2021, and concurrently published in The Lancet Oncology. “We are glad to see that copanlisib could be safely combined with rituximab for the long-term treatment of patients with HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEX DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTED The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial IMMUNOTHERAPY MARKET ESTIMATED TO REACH U.S. $115 BILLION Immunotherapy Market Estimated to Reach U.S. $115 Billion by 2023. According to a new report published by ReportsnReports, the Immunotherapy is expected to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. HIGHLIGHTS OF PRESCRIBING INFORMATION HEPATOTOXICITY FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an

FDA approved test.

ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

HIGHLIGHTS OF PRESCRIBING INFORMATION ADJUVANT … Subsequent doses at 6mg/kg as an intravenous infusion over 30–90 minutes every three weeks . Extending adjuvant treatment beyond one year is not recommended . STUDIES CONFIRM SAFETY AND EFFECTIVENESS OF COVID-19 Vaccination among cancer patients, hardest hit by the pandemic work very well. It's important to stress how well these patients did with

vaccines

WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to COMBINATION THERAPY ACHIEVED DURABLE REMISSION FOR A new study demonstrated that ibrutinib and venetoclax were effective when given together for high-risk and older patients with the disease. IMMUNOTHERAPY AFTER SURGERY EXTENDS DISEASE-FREE SURVIVAL Immunotherapy after surgery significantly improved disease-free survival for patients with clear-cell renal carcinoma a common type of

kidney cancer

GLIOBLASTOMA TRIAL WITH PERSONALIZED CANCER VACCINE SHOWS Data from the multi-center Phase 2 clinical trial of AV-GBM-1 (AIVITA Biomedical; NCT03400917), a personalized cancer vaccine, in patients 18 years or older with newly diagnosed glioblastoma (GBM) demonstrated a considerable increase in progression-free survival (PFS). RESEARCHERS FIND POSSIBLE LINK BETWEEN PROSTATE CANCER AND There may be an association between a few polymorphic variants of genes controlling neurotransmitter metabolism and the prognosis of

prostate cancer.

NIVOLUMAB + IPILIMUMAB SHOWS CONTINUED SURVIVAL IN Updated results from CheckMate-214 study (NCT02231749) show that more than 50% of patients treated with a combination of nivolumab (Opdivo®; Bristol Meyers Squibb), a programmed death-1 (PD-1) immune checkpoint inhibitor designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response, and ipilimumab (Yervoy®; Bristol Meyers Squibb)* were ADVANCING TREATMENT OPTIONS WITH IMMUNOTHERAPIES IN NON Antibody-drug conjugates Polatuzumab vedotin is a first-in-class anti-CD79b ADC. The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. SINGLE AND DUAL IMMUNOTHERAPY REGIMENS MAY OFFER IMPROVED Dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those positive for the immune checkpoint protein PD-L1. CLINICAL DEVELOPMENT The latest news and updates about clinical development in oncology and hematology from Onco'Zine and ADC Review | J. Antibody-drug

Conjugates.

HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEX DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

THE ONCO'ZINE BRIEF

The Onco'Zine Brief, a 100% independent radio broadcast/podcast concept developed for Public Radio by Sunvalley Communication, is unique, informative and educational program about cancer and cancer treatment. The Onco'Zine Brief is an educational program developed for public radio and designed for anyone who wishes to listen to comprehensive, updated and cutting-edge news and information about STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTED The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial IMMUNOTHERAPY MARKET ESTIMATED TO REACH U.S. $115 BILLION Immunotherapy Market Estimated to Reach U.S. $115 Billion by 2023. According to a new report published by ReportsnReports, the Immunotherapy is expected to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. CAN CANNABINOIDS HAVE A CURATIVE IMPACT ON A growing body of evidence suggests that cannabinoids have potent anti-tumor functions and could be used successfully in the treatment of Glioblastoma. As to whether any individual cannabinoid molecule or a blend of THC with CBD can play a curative role in the treatment for glioblastoma multiform, one needs to understand why up to now ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

ASH 2019: BRENTUXIMAB VEDOTIN IN COMBINATION WITH With five approved drugs on the market, ADCs have become a powerful class of therapeutic agents in oncology and hematology.. Continued evaluation “We continue to evaluate brentuximab vedotin in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need,” said Roger Dansey, MD, HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEX DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

THE ONCO'ZINE BRIEF

The Onco'Zine Brief, a 100% independent radio broadcast/podcast concept developed for Public Radio by Sunvalley Communication, is unique, informative and educational program about cancer and cancer treatment. The Onco'Zine Brief is an educational program developed for public radio and designed for anyone who wishes to listen to comprehensive, updated and cutting-edge news and information about STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTED The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial IMMUNOTHERAPY MARKET ESTIMATED TO REACH U.S. $115 BILLION Immunotherapy Market Estimated to Reach U.S. $115 Billion by 2023. According to a new report published by ReportsnReports, the Immunotherapy is expected to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. CAN CANNABINOIDS HAVE A CURATIVE IMPACT ON A growing body of evidence suggests that cannabinoids have potent anti-tumor functions and could be used successfully in the treatment of Glioblastoma. As to whether any individual cannabinoid molecule or a blend of THC with CBD can play a curative role in the treatment for glioblastoma multiform, one needs to understand why up to now ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

ASH 2019: BRENTUXIMAB VEDOTIN IN COMBINATION WITH With five approved drugs on the market, ADCs have become a powerful class of therapeutic agents in oncology and hematology.. Continued evaluation “We continue to evaluate brentuximab vedotin in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need,” said Roger Dansey, MD, WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE It was four years ago – in June 2017 – that the first World Kidney Cancer Day was celebrated. The international campaign was developed by the International Kidney Cancer Coalition (IKCC), a network of more than 45 Affiliate Organisations, to raise awareness for the little-known type of cancer. In the beginning, we focused on the basics about kidney cancer – what causes it, how to

THE ONCO'ZINE BRIEF

The Onco'Zine Brief, a 100% independent radio broadcast/podcast concept developed for Public Radio by Sunvalley Communication, is unique, informative and educational program about cancer and cancer treatment. The Onco'Zine Brief is an educational program developed for public radio and designed for anyone who wishes to listen to comprehensive, updated and cutting-edge news and information about FIVE-YEAR UPDATE OF ECHELON-1 AND ECHELON-2 AND OTHER Five-year follow-up Historically, a relapse of classical Hodgkin lymphoma (cHL) occurs within the first 5 years. “After five years of follow-up, an important clinical milestone, both the ECHELON-1 and ECHELON- 2 clinical trials demonstrate that brentuximab vedotin plus chemotherapy resulted in superior and durable outcomes when compared with standard chemotherapy regimens,” IMMUNOTHERAPY AFTER SURGERY EXTENDS DISEASE-FREE SURVIVAL Immunotherapy after surgery significantly improved disease-free survival for patients with clear-cell renal carcinoma a common type of

kidney cancer

STUDY WITH TRASTUZUMAB DUOCARMAZINE MEETS PRIMARY Results from the Phase III TULIP® study with Trastuzumab Duocarmazine in patients with HER 2+ Breast Cancer meets primary

endpoint

SINGLE AND DUAL IMMUNOTHERAPY REGIMENS MAY OFFER IMPROVED Dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those positive for the immune checkpoint protein PD-L1. A STUDY OF THE 4-1BB AGONIST ATOR-1017 SHOWS POSITIVE The activation-induced costimulatory molecule 4-1BB (CD137; TNFRS9), a surface glycoprotein that belongs to the tumor necrosis factor receptor family (TNFRSF9), is an important regulator of immune responses. Targeting 4-1BB or its natural ligand 4-1BB ligand, known as 4-1BBL, has important implications in many clinical conditions,

including cancer.

EDITORIAL TEAM

The editorial team of Onco'Zine and The Onco'Zine Brief consists of an Editor-in-Chief, Deputy Editors, and Consulting Editors. Members of the editorial team are chosen based on their demonstrated expertise in one or more areas of oncology or hematology and their active engagement in research. NEW SALIVA TEST DETECTS HEAD AND NECK CANCER A clinically validated ddPCR-based assay (NavDx™; Naveris Inc, Natick, MA) analyzed saliva for sequences of the HPV genome specific for HPV DNA released from malignant tumors. LARGE SCALE MULTI-OMIC ANALYSIS SUGGESTS MECHANISMS … LARGE SCALE MULTI-OMIC ANALYSIS SUGGESTS MECHANISMS OF RESISTANCE TO IMMUNOTHERAPY IN LEIOMYOSARCOMA Galina Lagos, Roman Groisberg, Don S. Dizon, Andrew Elliott, Tabitha Copeland, Andreas Seeber, HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. ASH 2020: BELANTAMAB MAFODOTIN + STANDARD THERAPIES INBELANTAMAB MAFODOTINBELANTAMAB APPROVAL During the American Society of Hematology (ASH) Annual Meeting and Exposition, hosted virtually from 5-8 December 2020 results from multiple studies discussing novel treatment options will be presented.. Belantamab mafodotin Among the presentations is new data from studies demonstrating the potential of belantamab mafodotin (GSK2857916; belantamab mafodotin-blmf; Blenrep®; STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

NIVOLUMAB + IPILIMUMAB SHOWS CONTINUED SURVIVAL IN Updated results from CheckMate-214 study (NCT02231749) show that more than 50% of patients treated with a combination of nivolumab (Opdivo®; Bristol Meyers Squibb), a programmed death-1 (PD-1) immune checkpoint inhibitor designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response, and ipilimumab (Yervoy®; Bristol Meyers Squibb)* were THALIDOMIDE'S SECRET PAST: THE LINK WITH NAZI GERMANYBAYER AND NAZI GERMANYBAYER NAZI EXPERIMENTS Photo 1.0: Otto Ambros (19 May 1901 – 23 July 1990), a German chemist, and Nazi war criminal who was known as “The Devil’s Chemist”, was directly involved with the research of chemical nerve agents, especially Sarin (known as “substance 146”) and tabun.He worked as the Chief of Production at IG Farben’s Buna Werke (synthetic) rubber plant at Monowitz in the Auschwitz complex. HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEXDARZALEX PRESCRIBING INFORMATIONDARZALEX PI DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTEDENFORTUMAB VEDOTIN AND PEMBROLIZUMABENFORTUMAB VEDOTIN IN BLADDER CANCER The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial CAN CANNABINOIDS HAVE A CURATIVE IMPACT ON Growing evidence suggests that cannabinoids have potent anti-tumor functions and could be used successfully in the treatment of GBM. The therapeutic effect of cannabinoids is based on the reduction of tumor growth via inhibition of tumor proliferation and angiogenesis, but also via induction of tumor cell death. ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

HIGHLIGHTS OF PRESCRIBING INFORMATION ADJUVANT … Subsequent doses at 6mg/kg as an intravenous infusion over 30–90 minutes every three weeks . Extending adjuvant treatment beyond one year is not recommended . HOME - ONCO'ZINE ONCO'ZINE PART OF PHYSICIAN'S WEEKLYARTICLESNEWSCAREERSCHANGING STRATEGIES IN THE WAR ON CANCERTHE

ONCO’ZINE BRIEF

Onco'Zine - part of the Physician's Weekly Oncology Network, has been is created to inform physicians treating patients with cancer. ASH 2020: BELANTAMAB MAFODOTIN + STANDARD THERAPIES INBELANTAMAB MAFODOTINBELANTAMAB APPROVAL During the American Society of Hematology (ASH) Annual Meeting and Exposition, hosted virtually from 5-8 December 2020 results from multiple studies discussing novel treatment options will be presented.. Belantamab mafodotin Among the presentations is new data from studies demonstrating the potential of belantamab mafodotin (GSK2857916; belantamab mafodotin-blmf; Blenrep®; STRO-002 SHOWS ENCOURAGING RESULTS IN PHASE I TRIAL IN Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.. The trial was designed to study the safety and anti-tumor activity results in heavily pre-treated patients with

ovarian cancer.

NIVOLUMAB + IPILIMUMAB SHOWS CONTINUED SURVIVAL IN Updated results from CheckMate-214 study (NCT02231749) show that more than 50% of patients treated with a combination of nivolumab (Opdivo®; Bristol Meyers Squibb), a programmed death-1 (PD-1) immune checkpoint inhibitor designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response, and ipilimumab (Yervoy®; Bristol Meyers Squibb)* were THALIDOMIDE'S SECRET PAST: THE LINK WITH NAZI GERMANYBAYER AND NAZI GERMANYBAYER NAZI EXPERIMENTS Photo 1.0: Otto Ambros (19 May 1901 – 23 July 1990), a German chemist, and Nazi war criminal who was known as “The Devil’s Chemist”, was directly involved with the research of chemical nerve agents, especially Sarin (known as “substance 146”) and tabun.He worked as the Chief of Production at IG Farben’s Buna Werke (synthetic) rubber plant at Monowitz in the Auschwitz complex. HIGHLIGHTS OF PRESCRIBING INFORMATION DARZALEXDARZALEX PRESCRIBING INFORMATIONDARZALEX PI DARZALEX® ®(daratumumab) injection DARZALEX (daratumumab) injection 2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE DARZALEX is indicated for the treatment of adult patients with multiple myeloma: • in combination with lenalidomide and dexamethasone in newly

diagnosed

COMBINATION ENFORTUMAB VEDOTIN + PEMBROLIZUMAB GRANTEDENFORTUMAB VEDOTIN AND PEMBROLIZUMABENFORTUMAB VEDOTIN IN BLADDER CANCER The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (Keytruda®) for the treatment of patients with unresectable locally advanced or metastatic urothelial CAN CANNABINOIDS HAVE A CURATIVE IMPACT ON Growing evidence suggests that cannabinoids have potent anti-tumor functions and could be used successfully in the treatment of GBM. The therapeutic effect of cannabinoids is based on the reduction of tumor growth via inhibition of tumor proliferation and angiogenesis, but also via induction of tumor cell death. ABOUT PETER HOFLAND, PH.D Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved

drug.

HIGHLIGHTS OF PRESCRIBING INFORMATION ADJUVANT … Subsequent doses at 6mg/kg as an intravenous infusion over 30–90 minutes every three weeks . Extending adjuvant treatment beyond one year is not recommended . ASH 2020: BELANTAMAB MAFODOTIN + STANDARD THERAPIES IN During the American Society of Hematology (ASH) Annual Meeting and Exposition, hosted virtually from 5-8 December 2020 results from multiple studies discussing novel treatment options will be presented.. Belantamab mafodotin Among the presentations is new data from studies demonstrating the potential of belantamab mafodotin (GSK2857916; belantamab mafodotin-blmf; Blenrep®; CANCER PATIENTS CONCERNED ABOUT VACCINE DESPITE FEW Altough cancer patients have a disproportionately higher COVID-19 mortality rate, they have nuanced COVID-19 vaccine attitudes. COVID19 AND BLADDER CANCER COVID19 and Bladder Cancer – Adapting to a New Reality. Typically in May, which is Bladder Cancer Awareness Month, my organization, the Bladder Cancer Advocacy Network or BCAN, is working feverishly to raise awareness of this disease, one of the most common cancers in the United States, yet one of the least known and understood. IMMUNOTHERAPY AFTER SURGERY EXTENDS DISEASE-FREE SURVIVAL Immunotherapy after surgery significantly improved disease-free survival for patients with clear-cell renal carcinoma a common type of

kidney cancer

STUDY: NO FDA-APPROVED TARGETED-THERAPY LIKELY TO BENEFIT According to a study published online in the March 16, 2021 edition of Oncotarget there is, unlike lung adenocarcinoma patients, no FDA-approved targeted therapy regimens available to benefit lung squamous cell carcinoma patients. The authors of the article concluded that this was ‘in spite of distinct genetic alterations identified in the tumor type.’ SINGLE AND DUAL IMMUNOTHERAPY REGIMENS MAY OFFER IMPROVED Dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those positive for the immune checkpoint protein PD-L1. A STUDY OF THE 4-1BB AGONIST ATOR-1017 SHOWS POSITIVE The activation-induced costimulatory molecule 4-1BB (CD137; TNFRS9), a surface glycoprotein that belongs to the tumor necrosis factor receptor family (TNFRSF9), is an important regulator of immune responses. Targeting 4-1BB or its natural ligand 4-1BB ligand, known as 4-1BBL, has important implications in many clinical conditions,

including cancer.

LARGE SCALE MULTI-OMIC ANALYSIS SUGGESTS MECHANISMS … LARGE SCALE MULTI-OMIC ANALYSIS SUGGESTS MECHANISMS OF RESISTANCE TO IMMUNOTHERAPY IN LEIOMYOSARCOMA Galina Lagos, Roman Groisberg, Don S. Dizon, Andrew Elliott, Tabitha Copeland, Andreas Seeber, END-OF-LIFE CARE ARCHIVES Welcome! Log into your account. your username. your password NEW SALIVA TEST DETECTS HEAD AND NECK CANCER A clinically validated ddPCR-based assay (NavDx™; Naveris Inc, Natick, MA) analyzed saliva for sequences of the HPV genome specific for HPV DNA released from malignant tumors.

__

__ __

__

__ __

__

__

__

* Home__

* Continued Medical Education

* Cancer A – Z__

* Leukemia

* Editorial Advisory Board__ * Join Our Editorial Advisory Board

* Contact Us

* Terms and Conditions

* Publications__

* ADC Review | J. Antibody-drug Conjugates__ * Resources for For Clinicians

* Drug Map (ADC)

* Peer Review Articles

* The Review

* Changing Strategies in the War on Cancer__ * Changing Strategies in the War on Cancer – Episode 1 * Changing Strategies in the War on Cancer – Episode 2 * Changing Strategies in the War on Cancer – Episode 3 * Journal of CAR T-Cell Therapy__

* About CAR T-cells

* Frequently Asked Questions

* Types of Articles

* Submit a Manuscript * The Onco’Zine Brief__ * The Onco’Zine Brief Episodes__ * The Onco’Zine Brief on PRX * The Onco’Zine Brief on Spreaker

* UK Health Radio

* Upcoming Programs | Shows * How to Support The Onco’Zine Brief * Corporate Underwriting and Sponsorship

* Programs | Shows

* The Onco’Zine Dossier__ * Thalidomide: A History__ * Thalidomide: In the Shadow of Death * Controversy: The involvement of Ciba AG in the development of

Thalidomide

* Thalidomide’s Secret Past: The Link with Nazi Germany * Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer * Smoking and Health__ * New Surgeon General’s Report Presents the Unfiltered Truth About

Tobacco

* Smoking and the Lost Legacy of the First Surgeon General’s Report on Smoking and Health * Tobacco Control in the United States Has Saved 8 Million Lives In

Last 50 Years

* Tobacco Companies are Finally Moving Closer to Revealing the Truth

about Smoking

* The Harmful Effects of Smoking: The Public Denial in the Early-mid

1960s

* Drug Approvals 2017 – 2020__ * Oncology & Hematology – FDA Drug Approvals 2018 * Oncology & Hematology – FDA Drug Approvals 2019 * Oncology & Hematology – FDA Drug Approvals 2020

* Articles__

* Latest Articles

* Expert Interviews

* Editorials and Commentaries * Eric Rosenthal Reports

* Publications

* News__

* Business & Economics * Clinical Development * Conference Coverage__ * COVID19 – Cancelled Medical Meetings 2020 * Oncology Directory__

* Join Today

* Event Agenda

* Video

* Careers

__

Search

* About

* Advertise

* Advisory Board

* Contact Us

__ __

__

__ __

__

__

__

Sign in

Welcome! Log into your account

your username

your password

Forgot your password? Get help

Password recovery

Recover your password

your email

A password will be e-mailed to you.

ONCO'ZINE

Advertisement #1

__

* Home__

* Continued Medical Education

* Cancer A – Z__

* Leukemia

* Editorial Advisory Board__ * Join Our Editorial Advisory Board

* Contact Us

* Terms and Conditions

* Publications__

* ADC Review | J. Antibody-drug Conjugates__ * Resources for For Clinicians

* Drug Map (ADC)

* Peer Review Articles

* The Review

* Changing Strategies in the War on Cancer__ * Changing Strategies in the War on Cancer – Episode 1 * Changing Strategies in the War on Cancer – Episode 2 * Changing Strategies in the War on Cancer – Episode 3 * Journal of CAR T-Cell Therapy__

* About CAR T-cells

* Frequently Asked Questions

* Types of Articles

* Submit a Manuscript * The Onco’Zine Brief__ * The Onco’Zine Brief Episodes__ * The Onco’Zine Brief on PRX * The Onco’Zine Brief on Spreaker

* UK Health Radio

* Upcoming Programs | Shows * How to Support The Onco’Zine Brief * Corporate Underwriting and Sponsorship

* Programs | Shows

* The Onco’Zine Dossier__ * Thalidomide: A History__ * Thalidomide: In the Shadow of Death * Controversy: The involvement of Ciba AG in the development of

Thalidomide

* Thalidomide’s Secret Past: The Link with Nazi Germany * Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer * Smoking and Health__ * New Surgeon General’s Report Presents the Unfiltered Truth About

Tobacco

* Smoking and the Lost Legacy of the First Surgeon General’s Report on Smoking and Health * Tobacco Control in the United States Has Saved 8 Million Lives In

Last 50 Years

* Tobacco Companies are Finally Moving Closer to Revealing the Truth

about Smoking

* The Harmful Effects of Smoking: The Public Denial in the Early-mid

1960s

* Drug Approvals 2017 – 2020__ * Oncology & Hematology – FDA Drug Approvals 2018 * Oncology & Hematology – FDA Drug Approvals 2019 * Oncology & Hematology – FDA Drug Approvals 2020

* Articles__

* Latest Articles

* Expert Interviews

* Editorials and Commentaries * Eric Rosenthal Reports

* Publications

* News__

* Business & Economics * Clinical Development * Conference Coverage__ * COVID19 – Cancelled Medical Meetings 2020 * Oncology Directory__

* Join Today

* Event Agenda

* Video

* Careers

__ __

A STUDY OF THE 4-1BB AGONIST ATOR-1017 SHOWS POSITIVE RESULTS

Editorial Team -

June 6, 2021

CANCER PATIENTS CONCERNED ABOUT VACCINE DESPITE FEW ADVERSE EFFECTS NEW SALIVA TEST DETECTS HEAD AND NECK CANCER – SHOWS PROMISING

RESULTS

COMPREHENSIVE GENOMIC AND TRANSCRIPTOMIC PROFILING PREDICTS PAN-TUMOR BENEFIT OF PEMBROLIZUMAB IMMUNOTHERAPY RESISTANCE IN LEIOMYOSARCOMA: SUBTYPES MAY BENEFIT FROM PERSONALIZED TREATMENTS

FEATURED

THE HISTORY, REALITY AND PROMISE OF IMMUNOTHERAPY FOR CANCER Daniel A. Vorobiof, MD

- February 25, 2021

REMEMBERING EMIL “JAY” FREIREICH—THE MAN WHO MADE VINCE DEVITA A

‘BELIEVER’

Eric T. Rosenthal -

February 13, 2021

THERANOSTICS TECHNOLOGY: A NEW APPROACH TO CANCER DIAGNOSIS AND

TREATMENT

Jill S. Helmke, D.Ph., N.Ph.

- December 29, 2020

EASING THE BURDEN OF CANCER BEYOND MEDICINE THROUGH THE ASTELLAS

ONCOLOGY C3 PRIZE

Andrew Krivoshik, MD, PhD

- September 17,

2020

PRECISION TECHNOLOGY TRANSFORMS THE WAY LEADING HOSPITALS DIAGNOSE AND TREAT PROSTATE CANCER

Steven Bardot, M.D.

- September 16, 2020 COMBINABILITY: ADDRESSING UNMET NEED IN AML David A. Roth, M.D. -

August 20, 2020

Advertisement

NEWS

A STUDY OF THE 4-1BB AGONIST ATOR-1017 SHOWS POSITIVE RESULTS

Editorial Team -

June 6, 2021

CANCER PATIENTS CONCERNED ABOUT VACCINE DESPITE FEW ADVERSE EFFECTS

Editorial Team -

June 6, 2021

NEW SALIVA TEST DETECTS HEAD AND NECK CANCER – SHOWS PROMISING

RESULTS

Editorial Team -

June 6, 2021

COMPREHENSIVE GENOMIC AND TRANSCRIPTOMIC PROFILING PREDICTS PAN-TUMOR BENEFIT OF PEMBROLIZUMAB

Editorial Team -

June 5, 2021

IMMUNOTHERAPY RESISTANCE IN LEIOMYOSARCOMA: SUBTYPES MAY BENEFIT FROM PERSONALIZED TREATMENTS

Peter Hofland, Ph.D

- June 4, 2021

COMMUNITY CANCER CENTERS AIM TO DIVERSIFY CANCER RESEARCH

Editorial Team -

June 4, 2021

PALLIATIVE CARE MAY IMPROVE OUTCOMES AND QUALITY OF LIFE FOR PATIENTS

WITH CANCER

Editorial Team -

June 4, 2021

LYMPHEDEMA: A CONSTANT REMINDER A PATIENT’S CANCER JOURNEY

Editorial Team -

June 3, 2021

CONFERENCE COVERAGE

A STUDY OF THE 4-1BB AGONIST ATOR-1017 SHOWS POSITIVE RESULTS

Editorial Team -

June 6, 2021

CANCER PATIENTS CONCERNED ABOUT VACCINE DESPITE FEW ADVERSE EFFECTS

Editorial Team -

June 6, 2021

NEW SALIVA TEST DETECTS HEAD AND NECK CANCER – SHOWS PROMISING

RESULTS

Editorial Team -

June 6, 2021

COMPREHENSIVE GENOMIC AND TRANSCRIPTOMIC PROFILING PREDICTS PAN-TUMOR BENEFIT OF PEMBROLIZUMAB

Editorial Team -

June 5, 2021

IMMUNOTHERAPY RESISTANCE IN LEIOMYOSARCOMA: SUBTYPES MAY BENEFIT FROM PERSONALIZED TREATMENTS

Peter Hofland, Ph.D

- June 4, 2021

NONINVASIVE NASAL SWAB TEST CAN SIGNIFICANTLY IMPROVE EARLY LUNG

CANCER DETECTION

Peter Hofland, Ph.D

- May 19, 2021

Advertisement

EDITORIAL

HUMANIZING HEALTHCARE: A CONVERSATION WITH SUMMER KNIGHT, MD, MBA

Editorial Team -

May 28, 2021

WORLD KIDNEY CANCER DAY 2021: WE NEED TO TALK ABOUT HOW WE’RE

FEELING

Rachel Giles, MD -

May 20, 2021

A SPACESHIP ON MARS AND SCREENING FOR GYNECOLOGIC CANCER

Valena Wrtight, MD

- April 6, 2021

ARE CYTOLOGY AND IMAGING ADEQUATE FOR THE DIAGNOSTIC MANAGEMENT OF

BRAIN METASTASIS?

Michael C. Dugan, M.D.

- April 1, 2021

REVEALING THE BLIND SPOT IN CANCER TREATMENT WITH HOST RESPONSE

PROFILING

Ofer Sharon, MD, MBA -

March 22, 2021

REMEMBERING EMIL “JAY” FREIREICH—THE MAN WHO MADE VINCE DEVITA A

‘BELIEVER’

Eric T. Rosenthal -

February 13, 2021

ERIC ROSENTHAL REPORTS REMEMBERING EMIL “JAY” FREIREICH—THE MAN WHO MADE VINCE DEVITA A

‘BELIEVER’

Eric T. Rosenthal -

February 13, 2021

WHY WERE TOP HHS OFFICIALS? INTERVIEWS THWARTED BY THEIR PRESS

OFFICES?

Eric T. Rosenthal -

March 5, 2019

EXPERT INTERVIEWS

INTERVIEW: THE DEVELOPMENT OF SERMONIX’ LASOFOXIFENE IN ADVANCED OR METASTATIC BREAST CANCER

Editorial Team -

September 12, 2020

JORDAN GAUTHIER – ABOUT THE NCCN GUIDELINES FOR PATIENTS AND THE

SIDE EFFECTS OF...

Editorial Team -

August 12, 2020

KNOWLEDGE ALONE IS NOT ENOUGH TO DEFEAT CANCER

Peter Hofland, Ph.D

- November 2, 2018

Advertisment #12

A STUDY OF THE 4-1BB AGONIST ATOR-1017 SHOWS POSITIVE RESULTS

Editorial Team -

June 6, 2021

CANCER PATIENTS CONCERNED ABOUT VACCINE DESPITE FEW ADVERSE EFFECTS

Editorial Team -

June 6, 2021

NEW SALIVA TEST DETECTS HEAD AND NECK CANCER – SHOWS PROMISING

RESULTS

Editorial Team -

June 6, 2021

DAIICHI SANKYO OUT-LICENSES INVESTIGATIONAL AGENT DS-6051 TO ANHEART

THERAPEUTICS

Peter Hofland, Ph.D

- December 19, 2018

HOW MEANINGFUL WILL CHANGES BE TO ETHICAL GUIDELINES FOLLOWING JOSE

BASELGA’S FALL?

Eric T. Rosenthal -

October 9, 2018

REVERSAL OF FORTUNE: HOW A VILIFIED DRUG BECAME A LIFE-SAVING AGENT IN

THE ‘WAR’...

Peter Hofland, Ph.D

- November 30, 2013

* News2386

* Conference Coverage359 * Clinical Trial Updates232 * Research & Development188 * Business & Economics112

* Cancer Risk101

* Regulatory Updates92 * Clinical development78

* Resource Guide78

* Editorials and Commentaries74 ABOUT USOnco'Zine - The International Oncology Network, has been created to inform, educate, and support physicians and healthcare professionals treating cancer patients. The Journal reports on current research and development in oncology and hematology and contains clinical information created specifically for healthcare

professionals.

FOLLOW US __ __

__

__ __

__

__

* Home

* Continued Medical Education

* Cancer A – Z

* Leukemia

* Editorial Advisory Board * Join Our Editorial Advisory Board

* Contact Us

* Terms and Conditions

* Publications

* ADC Review | J. Antibody-drug Conjugates * Resources for For Clinicians

* Drug Map (ADC)

* Peer Review Articles

* The Review

* Changing Strategies in the War on Cancer * Changing Strategies in the War on Cancer – Episode 1 * Changing Strategies in the War on Cancer – Episode 2 * Changing Strategies in the War on Cancer – Episode 3 * Journal of CAR T-Cell Therapy

* About CAR T-cells

* Frequently Asked Questions

* Types of Articles

* Submit a Manuscript * The Onco’Zine Brief * The Onco’Zine Brief Episodes * The Onco’Zine Brief on PRX * The Onco’Zine Brief on Spreaker

* UK Health Radio

* Upcoming Programs | Shows * How to Support The Onco’Zine Brief * Corporate Underwriting and Sponsorship

* Programs | Shows

* The Onco’Zine Dossier * Thalidomide: A History * Thalidomide: In the Shadow of Death * Controversy: The involvement of Ciba AG in the development of

Thalidomide

* Thalidomide’s Secret Past: The Link with Nazi Germany * Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer * Smoking and Health * New Surgeon General’s Report Presents the Unfiltered Truth About

Tobacco

* Smoking and the Lost Legacy of the First Surgeon General’s Report on Smoking and Health * Tobacco Control in the United States Has Saved 8 Million Lives In

Last 50 Years

* Tobacco Companies are Finally Moving Closer to Revealing the Truth

about Smoking

* The Harmful Effects of Smoking: The Public Denial in the Early-mid

1960s

* Drug Approvals 2017 – 2020 * Oncology & Hematology – FDA Drug Approvals 2018 * Oncology & Hematology – FDA Drug Approvals 2019 * Oncology & Hematology – FDA Drug Approvals 2020

* Articles

* Latest Articles

* Expert Interviews

* Editorials and Commentaries * Eric Rosenthal Reports

* Publications

* News

* Business & Economics * Clinical Development * Conference Coverage * COVID19 – Cancelled Medical Meetings 2020 * Oncology Directory

* Join Today

* Event Agenda

* Video

* Careers

� 2001 - 2020 Sunvalley Communication, LLC. All Rights Reserved.

X